Trinity Biotech ( (TRIB) ) has issued an announcement.
Trinity Biotech announced a positive update regarding the U.S. government’s funding for HIV testing programs using their rapid HIV tests. On February 1, 2025, the U.S. Department of State confirmed a waiver that ensures continued funding under the President’s Emergency Plan for AIDS Relief, allowing the company to maintain its operations in this critical area.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology firm based in Ireland, focusing on human diagnostics and diabetes management solutions, including wearable biosensors.
YTD Price Performance: -5.16%
Average Trading Volume: 2,223,627
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.23M
For detailed information about TRIB stock, go to TipRanks’ Stock Analysis page.